Joseph M Tuscano

Trials

Studies that name Joseph M Tuscano as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:45 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT06905509 · Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

  University of California, Davis · recruiting · Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements · study chair
• Ph2
  NCT06854159 · Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy

  University of California, Davis · recruiting · Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma · principal investigator
• Ph1
  NCT06015880 · Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

  National Cancer Institute (NCI) · recruiting · Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma · principal investigator
• Ph1
  NCT05967533 · The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors

  University of California, Davis · suspended · Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm · principal investigator
• Ph2
  NCT05600686 · Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma

  University of California, Davis · active not recruiting · Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements · principal investigator
• Ph2
  NCT04587687 · Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

  University of California, Davis · recruiting · Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma · principal investigator
• Ph1
  NCT04578600 · CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

  Joseph Tuscano · completed · Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia · principal investigator
• Ph2
  NCT04450173 · Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma

  University of California, Davis · active not recruiting · Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma · principal investigator
• Ph1
  NCT02568553 · Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

  National Cancer Institute (NCI) · completed · Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma · principal investigator
• Ph2
  NCT00848328 · Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma

  University of California, Davis · terminated · Lymphoma · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-11 23:45 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

• Fermented wheat germ proteins;mechanistic, immunologic and pre-clinical canine studies
  I01BX004669 · VA · VA NORTHERN CALIFORNIA HEALTH CARE SYS · fiscal years 2020 to 2025
  Same name and institution; not confirmed by an ID
• CD22-targeted Therapeutics for the Treatment of Lung Cancer
  I01BX000961 · VA · VA NORTHERN CALIFORNIA HEALTH CARE SYS · fiscal years 2013 to 2016
  Same name and institution; not confirmed by an ID
• PHASE II TRIAL OF BEVACIZUMAB VS BEVACIZUMAB, THALIDOMIDE FOR RELAPSED/REFRACTOR
  M01RR019975 · NCRR · UNIVERSITY OF CALIFORNIA AT DAVIS · fiscal years 2004 · $6,474 awarded in 2004
  Same name and institution; not confirmed by an ID
• GCKR MEDIATED SIGNAL TRANSDUCTION AND LEUKEMIC TRANSFORM
  K08CA077331 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · fiscal years 1998 to 2000 · $84,780 awarded in 2000
  Same name and institution; not confirmed by an ID

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Integrated Cancer Biology Program
  P30CA093373 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Wolf-Dietrich Heyer · fiscal years 2012 to 2026
  Named on NCT06905509, NCT06854159, NCT05967533, NCT05600686, NCT04587687, NCT04578600, NCT04450173
• Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTN
  UM1CA186717 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI A. Dimitrios Colevas, Alexey V. Danilov, PRIMO N. LARA, HEINZ JOSEF LENZ · fiscal years 2014 to 2026
  Named on NCT06015880, NCT02568553
• North American Star Consortium
  UM1CA186644 · NCI · UNIVERSITY HEALTH NETWORK · PI Philippe Bedard, Kevin D Courtney, Steven Grant, Salma Jabbour, Jeffrey Lancet, Devalingam Mahalingam, Lillian L Siu, JONATHAN C TRENT · fiscal years 2014 to 2026
  Named on NCT02568553